Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
TOLECTIN 600 is a nonsteroidal anti-inflammatory drug (NSAID) containing tolmetin sodium, approved in 1976 for oral administration. It is indicated for the treatment of rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. Tolmetin works by inhibiting prostaglandin synthesis through COX enzyme inhibition, reducing inflammation and pain.
As a legacy NSAID approaching loss of exclusivity with moderate competitive pressure (30%), team focus is shifting toward lifecycle extension, cost management, and preparation for generic competition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and LOE approaching, TOLECTIN 600 offers limited career advancement opportunities and represents a legacy product maintenance role rather than a growth or innovation platform. Professionals joining this team should expect focus on cost optimization, generic transition management, and defending market share rather than launching new initiatives or expanding indications.
Worked on TOLECTIN 600 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.